Irina Kadiyala

Irina Kadiyala, Ph.D, is Senior Director of CGT Process Development group. She has more than 25 years of industrial experience. Her group work was responsible for filing a BLA for CASGEVY, a treatment for SCD and TDT, the first approved CRISPR-Cas9-based product. In her current position, she is heading a group focused on process development and characterization studies for new Vertex modalities.